Home Mechanical Ventilation: A Canadian Thoracic Society Clinical Practice Guideline by McKim, Douglas A. et al.
Can Respir J Vol 18 No 4 July/August 2011 197
Home mechanical ventilation: A Canadian Thoracic 
Society clinical practice guideline
Douglas A McKim MD FRCPC FCCP DABSM1, Jeremy Road BSc MD FRCPC2, Monica Avendano MD FRCPC3,  
Steve Abdool BA MA PhD(C)3,4, Fabien Côté MD FRCPC CHA5, Nigel Duguid MB ChB FRCPC MRCP6,  
Janet Fraser BSc RRT7, François Maltais MD FRCPC8, Debra L Morrison MD FRCPC9, Colleen O’Connell MD FRCPC10, 
Basil J Petrof MD FRCPC11, Karen Rimmer MD FRCPC12, Robert Skomro MD FRCP DABSM13;  
Canadian Thoracic Society Home Mechanical Ventilation Committee
1Division of Respirology, University of Ottawa, and Respiratory Rehabilitation Services, Ottawa Hospital Sleep Centre, Ottawa, Ontario; 2Division of 
Respiratory Medicine and The Lung Centre, University of British Columbia, Provincial Respiratory Outreach Program, Vancouver, British Columbia; 
3Respiratory Medicine, West Park Healthcare Centre, University of Toronto; 4Centre for Clinical Ethics at St Michael’s Hospital, West Park Healthcare 
Centre, and University of Toronto, Toronto, Ontario; 5Laval University, Québec, Québec; 6Eastern Health, Memorial University, St John’s, 
Newfoundland and Labrador; 7Respiratory Therapy Services, West Park Healthcare Centre, Toronto, Ontario; 8Research Centre, University Institute 
of Cardiology and Lung Health for Québec, Laval University, Québec, Québec; 9Sleep Clinic and Laboratory, Queen Elizabeth II Health Sciences 
Centre and Dalhousie University, Halifax, Nova Scotia; 10Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick; 11McGill University 
Health Centre, Montreal, Quebec; 12University of Calgary, Calgary, Alberta; 13University of Saskatchewan, Saskatoon, Saskatchewan
Correspondence: Dr Douglas A McKim, Division of Respirology, University of Ottawa, 501 Smyth Road, Unit 1201, Ottawa, Ontario K1H 8M2. 
Telephone 613-737-8899 ext 75318, fax 613-736-9054, e-mail dmckim@ottawahospital.on.ca
Reprint requests: Canadian Thoracic Society, 300-1750 Courtwood Crescent, Ottawa, Ontario K2C 2B5. Telephone 613-569-6411, fax 613-569-8860,  
e-mail cts info@lung.ca
More than 50 years ago, individuals with polio courageously led the challenge of maintaining mechanical ventilation outside of insti-
tutions and quietly initiated a more independent, patient-centered and 
collaborative approach to respiratory health care. Today, the drivers for 
home mechanical ventilation (HMV) are different. The rising costs of 
hospital care, the advent of commercially available noninvasive masks 
and positive-pressure ventilators have fuelled greater demand for HMV. 
However, the desire of individuals to maintain a quality of life (QoL) in 
their homes remains the prevailing impetus. The present HMV clinical 
practice guideline is intended to be a resource for physicians, health 
care providers, policy makers and individuals at risk for or currently 
using ventilatory support in the home. The objective is to identify 
and support ventilated patients who are presently at home, as well as 
those transitioning to home-based care where QoL is greatest and 
costs are minimized. Developed by the Canadian Thoracic Society 
(CTS), these guidelines intend to provide the most up-to-date infor-
mation and evidence-based recommendations to enable practitioners 
to manage the provision of preventive airway management and home 
ventilation.
These guidelines are composed of disease-specific sections in addi-
ton to overriding subjects such as ethical considerations, transition to 
home and airway clearance. In the discipline of respiratory medicine, 
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Increasing numbers of patients are surviving episodes of prolonged 
mechanical ventilation or benefitting from the recent availability of user-
friendly noninvasive ventilators. Although many publications pertaining 
to specific aspects of home mechanical ventilation (HMV) exist, very few 
comprehensive guidelines that bring together all of the current literature 
on patients at risk for or using mechanical ventilatory support are avail-
able. The Canadian Thoracic Society HMV Guideline Committee has 
reviewed the available English literature on topics related to HMV in 
adults, and completed a detailed guideline that will help standardize and 
improve the assessment and management of individuals requiring noninva-
sive or invasive HMV. The guideline provides a disease-specific review of 
illnesses including amyotrophic lateral sclerosis, spinal cord injury, muscu-
lar dystrophies, myotonic dystrophy, kyphoscoliosis, post-polio syndrome, 
central hypoventilation syndrome, obesity hypoventilation syndrome, and 
chronic obstructive pulmonary disease as well as important common 
themes such as airway clearance and the process of transition to home. The 
guidelines have been extensively reviewed by international experts, allied 
health professionals and target audiences. They will be updated on a regu-
lar basis to incorporate any new information.
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La ventilation mécanique à domicile : un guide de 
pratique clinique de la Société canadienne de 
thoracologie
De plus en plus de patients survivent à des épisodes de ventilation 
mécanique prolongés ou profitent de l’accès récent à des ventilateurs 
non effractifs conviviaux. Même s’il existe de nombreuses publications 
sur des aspects précis de la ventilation mécanique à domicile (VMD), 
très peu de lignes directrices complètes rassemblent toutes les publica-
tions à jour sur les patients vulnérables à l’utilisation d’un soutien 
ventilatoire mécanique. Le comité des lignes directrices sur la VMD de 
la Société canadienne de thoracologie a analysé les publications anglo-
phones disponibles sur les sujets liés à la VMD chez les adultes et a 
élaboré des lignes directrices détaillées qui contribueront à normaliser 
et à améliorer l’évaluation et la prise en charge des personnes ayant 
besoin d’une VMD non effractive ou effractive. Les lignes directrices 
fournissent une analyse propre à certaines maladies, y compris la 
sclérose latérale amyotrophique, le traumatisme médullaire, la dystro-
phie musculaire, la dystrophie myotonique, la cyphoscoliose, le syn-
drome post-polio, le syndrome d’hypoventilation centrale, le syndrome 
obésité-hypoventilation et la maladie pulmonaire obstructive chro-
nique, et abordent des thèmes courants importants, tels que la 
clairance des voies aériennes et le processus de transition vers le domi-
cile. Les guides de pratique ont fait l’objet de révisions approfondies 
par des experts internationaux, des professionnels paramédicaux et des 
publics ciblés. Ils seront régulièrement mis à jour afin d’y intégrer toute 
nouvelle information.
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there are extremely few prospective or randomized trials. As a result, 
most recommendations are based on retrospective or descriptive stud-
ies and, to a great extent, on consensus of the CTS HMV committee.
Recommendations strive to achieve a balance between an excep-
tional standard of care illustrated in the literature and the reality of 
health care in Canada, where geographical and economic barriers may 
require compromise to ensure the availability of the best care possible. 
This approach may also allow greater applicability to jurisdictions 
where, for example, polysomnography may be unavailable or so diffi-
cult to obtain as to present unacceptable barriers to appropriate, timely 
introduction of noninvasive ventilation (NIV). Nevertheless, some 
subjects considered to be important by the committee are not 
addressed in the literature. Some jurisdictions have access to provin-
cial ventilator pools, in which equipment and knowledgeable health 
care professionals are available at relatively minimal cost, to ensure 
the success of HMV. The literature does not address questions 
regarding government-funded equipment pools. On important issues 
for which literature is lacking, but strong expert opinion was available, 
recommendations were made by the HMV Guideline Committee.
No article in the literature, to our knowledge, addressed the appro-
priate addition of a backup ventilation system aside from patients fully 
ventilated through a tracheostomy; accordingly, it remains uncertain 
as to precisely when an individual on NIV should have an additional 
ventilator or when alarms should be required. The general recognition 
that NIV is not designed for full 24 h life support has resulted in this 
uncertainty. However, patients are, in fact, using 24 h NIV, without 
which they are at risk for acute respiratory failure. This area of risk 
management will need attention in future investigations. Throughout 
the recommendations, it is assumed (aside from that clearly stated in 
the section on Transition to Home) that appropriate training will be 
provided to patients and caregivers.
These guidelines do not address negative-pressure body ventilators 
or abdominal ventilators because positive-pressure ventilators have, 
with few exceptions, completely replaced negative-pressure ventilators 
in the home. Although potentially of significant clinical value in the 
follow-up of patients on NIV, no recommendations are made on the 
use of digital information and downloads from bilevel devices. 
Additional research is desperately needed to address many of these 
critical questions.
The present guideline focused on HMV in the adult population. 
There are some important differences in HMV in the pediatric population 
and also in the transition phase into adult programs. The committee rec-
ognized these areas and hope that future guidelines will address them.
Preventive airway management and HMV is a complex, interdisci-
plinary component of respiratory care and clinical practice. This com-
ponent requires a continuum of chronic disease management involving 
many layers of expertise from government and professional education 
to home care services, acute and chronic health facilities and 
independent living facilities. The goal of HMV – and, thereby the goal 
of these guidelines – is to ensure the continued health of patients at 
risk for and currently using ventilatory support in their homes where 
QoL is greater and the cost to the health care system is the lowest.
The present document represents the executive summary of the 
guideline. The source document, which is more detailed and 
includes research questions identified by the committee, is available 
online at www.respiratoryguidelines.ca/guideline/home-ventilation.
EXECUTIVE SUMMARY
Question
What evidence is available to inform the practice of HMV and lead to 
better individual, caregiver and system outcomes?
Objective
The objective of the present clinical practice guideline is to provide 
guidance on the role of mechanical ventilation in the home setting. A 
guideline on this topic is needed to inform best practices, provide a 
basis to identify gaps in care and provide direction for future research.
Target population
The current clinical practice guideline applies to all adult individuals 
who are at risk for or are using HMV. Individuals with amyotrophic 
lateral sclerosis (ALS), central hypoventilation syndrome (CHS), 
chronic obstructive pulmonary disease (COPD), kyphoscoliosis, obes-
ity hypoventilation syndrome (OHS), spinal cord injury (SCI), 
Duchenne muscular dystrophy (DMD), muscular dystrophies (MDs) 
other than DMD, myopathies and myotonic dystrophy (Steinert’s 
muscular dystrophy [SMD]) are of special interest and are considered 
individually in the present clinical practice guideline.
Target users
The present clinical practice guideline is intended for use by the 
health care teams that care for individuals who are at risk for or require 
ventilatory assistance. Respirologists, physiatrists, neurologists, family 
practitioners, nurses, respiratory therapists, physiotherapists and other 
health care professionals can use these guidelines to help inform their 
clinical practice with regard to HMV. This guideline is also intended 
for use by ventilator-assisted individuals (VAIs) and their caregivers to 
help them make informed decisions with regard to HMV.
METHODOLOGY
Guideline development
This clinical practice guideline was developed according to the con-
vention of the 23-item AGREE II instrument – the current gold stan-
dard in the appraisal of practice guidelines (1). The HMV Expert 
Committee, comprising respirologists, a physiatrist and a respiratory 
therapist with content expertise in each of the topic areas, a research 
coordinator and a methodologist conducted a systematic review of the 
literature that was current to June 2010. Before completion, the guide-
line was distributed to content experts in Canada and other countries 
with similar programs for the opportunity to provide feedback con-
cerning the collection and interpretation of the evidence, as well as 
the development and content of the recommendations. Key stake-
holders, from the Ministry of Health, VAIs, interested groups includ-
ing respiratory therapists, ALS, MD and spinal cord networks were 
invited to review and provide input on the document. Final consensus 
on the recommendations from the CTS HMV Committee was reached 
through a formal voting process that was anonymized. The literature 
will be periodically reviewed (biannually) and the guideline will be 
updated as new or compelling evidence is identified.
Literature search strategy
The literature was searched using MEDLINE (OVID: 1980 through 
June 2010), Embase OVID: (1980 through June 2010), HealthStar 
(1980 through June 2010), the Cochrane Library (OVID: Issue 1, 
2009), the Canadian Medical Association InfoBase and the National 
Guideline Clearinghouse. Reference lists of related papers and recent 
review articles were also scanned for additional citations.
Study selection criteria
Articles were selected for inclusion in the systematic review of the 
evidence if they reported data on the role of HMV among adult indi-
viduals who require ventilatory assistance. Studies were required to 
report data on at least one of the following outcomes of interest: sur-
vival, pulmonary function, sleep parameters, airway clearance tech-
niques, cognition, VAIs and caregiver QoL, making the transition to 
home or ethical considerations.
Critical appraisal
The strengths and weaknesses of the evidence were carefully considered 
in the generation of the recommendations. Although the majority of the 
evidence in this topic area is modest, the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) methodology was 
used to inform the generation of recommendations and critically appraise 
the strength of the evidence (2). When no evidence was available, the 
committee made a recommendation when consensus was reached; the 
recommendation was subsequently identified as such (Table 1). 
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SECTION I. AIRWAY CLEARANCE IN  
AT-RISK AND VAIs
Introduction
Ventilatory support is capable of reliably providing volume and pres-
sure for adequate ventilation, but this can only be assured if the air-
ways remain clear of mucus and debris. Airways encumbered by 
secretions will result in reduced ventilation and contribute to low 
ventilation/perfusion states, which in turn, can lead to resorption atel-
ectasis and shunt. Retained secretions increase the risk for pneumonia 
and respiratory failure. During long-term invasive tracheostomy venti-
lation, airway clearance (usually by suctioning) is routine. However, 
during NIV, there is a tendency to neglect the need for airway clear-
ance techniques and focus on ventilation alone. In neuromuscular 
disease (NMD) patients, recognizing this principle is equally import-
ant – even before the need for ventilatory support – and is critical in 
addressing the issues of worsening respiratory mechanics and the 
inability to cough effectively.
Key evidence
Prospective observational studies and retrospective reviews based on 
small numbers of patients comprise most of the evidence base for air-
way clearance in at-risk and VAIs. In the absence of high-quality evi-
dence, the strength of the recommendations was determined by 
consensus within the committee.
Education and preventive strategies in airway clearance must pre-
cede the need for mechanical ventilation whenever possible. Education 
in preventive airway clearance helps prepare a patient and may pre-
vent acute crises. In the absence of contraindications such as risk for 
barotrauma or unconsciousness, lung volume recruitment (LVR [ie, air 
stacking]) techniques should be introduced with measurement of peak 
cough flows (PCFs) and maximum insufflation capacity (MIC) (1,2) 
in those with PCFs <270 L/min. Figure 1-1 illustrates the important 
difference between spontaneous vital capacity (VC [red curve]) and 
after LVR (MIC [blue curve]) in kyphoscoliosis (post-polio) and tetra-
plegia. There is a lower volume response in more mechanically 
restricted individuals with kyphoscoliosis.
This recommendation is informed by three retrospective cohort stud-
ies, one case series and one consensus document (1-5). Bach et al (1) 
studied 22 and 24 DMD, pre- and post-protocol patients, respectively. 
Kang and Bach (2) studied 71 preprotocol and 23 protocol NMD 
patients. Tzeng and Bach (3) studied 43 mixed NMD patients by per-
forming air-stacking and MIC measurements. More recently, a case 
series (4) demonstrated that 94.9% of 78 DMD patients were capable 
of significantly increasing their PCFs with LVR. There was also one 
consensus document from the American Thoracic Society (5).
Manually assisted coughing (MAC) is recommended alone or in 
combination with LVR to increase PCFs to >270 L/min. From the two 
observational studies that informed this recommendation (6,7), one 
(21 patients with NMD [6]) demonstrated that LVR and MAC may 
significantly increase cough capacity; the other (61 DMD patients [7]) 
demonstrated significant increases in PCF with MAC and in combina-
tion with air stacking. One consensus document suggested a minimum 
desirable PCF of 270 L/min (5). In the absence of contraindications (as 
above), mechanical in-exsufflation (MI-E) is recommended for patients 
unable to achieve PCFs >270 L/min with LVR and/or MAC, particu-
larly during respiratory infection. Evidence includes one observational 
intervention study (21 patients with NMD [6]) that demonstrated that 
peak expiratory flows can be significantly increased above those with 
LVR and MAC with use of MI-E. The other evidence is one retro-
spective cohort study of 22 NMD patients who were provided standard 
care and 24 patients on ‘protocol’, which included the use of MI-E, 
and demonstrated fewer hospital days (1). One case report described 
the use of MI-E to treat respiratory failure during lower respiratory 
infection in ALS (8). A retrospective cohort study of 41 patients with 
NMD demonstrated significant reductions in subsequent hospital days 
whether on spontaneous, part-time support or full-time NIV, once 
initiated on a respiratory protocol that included MI-E (3). This 
approach is summarized in Figure 1-2.
For invasive ventilation, long-term tracheostomies should be 
cuffless or cuff deflated, if possible. One observational study (9) dem-
onstrated the safety and value of uncuffed or cuffless tracheostomy 
TAble 1
Grading recommendations
Grade of recommendation/
description benefit versus risk and burdens
Methodological quality of  
supporting evidence Implications
1A/strong recommendation, 
high-quality evidence
Benefits clearly outweigh risk and 
burdens, or vice versa
RCTs without important limitations or 
overwhelming evidence from observational 
studies
Strong recommendation, can apply to most 
patients in most circumstances without 
reservation
1B/strong recommendation, 
moderate quality evidence
Benefits clearly outweigh risk and 
burdens or vice versa
RCTs with important limitations (inconsistent 
results, methodological flaws, indirect or 
imprecise) or exceptionally strong evidence 
from observational studies
Strong recommendation, can apply to most 
patients in most circumstances without 
reservation
1C/strong recommendation, 
low-quality or very  
low-quality evidence
Benefits clearly outweigh risk and 
burdens, or vice versa
Observational studies or case series Strong recommendation but may change 
when higher quality evidence becomes 
available
2A/weak recommendation, 
high-quality evidence
Benefits closely balanced with risks and 
burden
RCTs without important limitations or 
overwhelming evidence from observational 
studies
Weak recommendation, best action may 
differ depending on circumstances, 
patients’ or social values
2B/weak recommendation, 
moderate-quality evidence
Benefits closely balanced with risks and 
burden
RCTs with important limitations (inconsistent 
results, methodological flaws, indirect or 
imprecise) or exceptionally strong evidence 
from observational studies
Weak recommendation, best action may 
differ depending on circumstances, 
patients’ or social values
2C/weak recommendation, 
low-quality or very  
low-quality evidence
Uncertainty in the estimates of benefits, 
risks and burden; benefits, risk and 
burden may be closely balanced
Observational studies or case series Very weak recommendations; other 
alternatives may be equally reasonable
From reference 2. RCTs Randomized controlled trials
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tubes. Unless contraindicated due to aspiration risk, cuffless venti-
lation allows for the use of speaking valves to augment speech as 
well as allowing for independent performance of LVR techniques; 
however, adequate, sustained gas exchange must be ensured (8). For 
invasive ventilation, heated humidity is recommended over a heat-
humidity exchanger. Three prospective randomized trials involv-
ing 14, 24 and 15 spontaneously and 11 fully ventilated patients, 
respectively (10-12), demonstrated adverse effects of heat-humidity 
exchangers on dead space, minute ventilation and respiratory rate, 
which are particularly relevant to patients with spontaneous venti-
lation. Furthermore, a meta-analysis (13) did not find significant 
differences in important clinical outcomes such as pneumonia, mor-
tality or morbidity.
Insufficient evidence exists in long-term tracheostomy-ventilated 
patients to fully inform the technique of tracheostomy suctioning. The 
committee recommends that minimally invasive suctioning – instead 
of deep suctioning – be used when possible. One consensus document 
indicated the effectiveness of shallow suctioning in patients with 
some cough ability (14), and a randomized controlled trial (RCT) of 
intensive care unit-ventilated patients demonstrated the equivalence 
of minimally invasive suctioning with fewer adverse effects (15). 
MI-E and MAC for tracheostomy airway clearance should be strongly 
considered to complement or replace deep suctioning. This recom-
mendation is informed by one retrospective (n=18), one prospective 
crossover (n=8) and one prospective controlled trial (n not specified) 
(16-18) demonstrating that MI-E for tracheal clearance is both effect-
ive and preferred by patients familiar with both MI-E and invasive 
suctioning. Clean, as opposed to sterile, conditions are adequate for 
home secretion clearance and suctioning. Two professional consensus 
documents suggest that a fully sterile environment is not necessary for 
tracheostomy management in the home, but that clean conditions are 
adequate (19,20).
Conclusion
Adequate airway clearance may be the single most critical therapeutic 
intervention that prevents acute respiratory failure, undesired intuba-
tion and tracheostomy in patients at risk for or using NIV. Airway 
clearance strategies may help to maintain lung and chest wall compli-
ance through its positive effects on MIC (21) and peak expiratory 
flows. Individuals who are at greatest risk are those with impairment of 
inspiratory and expiratory muscles and glottic dysfunction. Many non-
invasive techniques are well established including LVR, MAC and 
MI-E. Several of these noninvasive strategies can also be applied to 
tracheostomy-ventilated patients in whom cuff inflation and invasive 
suctioning have traditionally been the sole method of ventilation and 
airway clearance. More research is needed to identify the ideal meth-
ods of noninvasive and invasive airway clearance in the home to 
optimize the effectiveness of mechanical ventilation and enhance 
QoL for VAIs.
SECTION I. RECOMMENDATIONS 
For at-risk individuals and patients using NIV:
1. Education and preventive strategies in airway clearance must 
precede the need for mechanical ventilation whenever possible. 
(Consensus) 
2. In the absence of contraindications, LVR techniques should be 
introduced with the measurement of PCFs and MIC in those 
with PCFs <270 L/min. (Grade of recommendation 1C)
3. MAC is recommended alone or in addition to LVR to increase 
PCFs to >270 L/min. (Grade of recommendation 1C)
4. In the absence of contraindications, MI-E should be 
recommended for patients unable to achieve PCFs >270 L/min 
with LVR and/or MAC, particularly during respiratory infection. 
(Grade of recommendation 1C)
For invasive ventilation:
1. As long as adequate, sustained ventilation is ensured, long-term 
tracheostomies should be cuffless or cuff deflated if possible. 
(Grade of recommendation 2C)
2. Heated humidity is recommended over heat-humidity 
exchangers. (Grade of recommendation 1A)
3. Minimally invasive rather than deep suctioning is recommended 
when possible. (Grade of recommendation 2B) 
4. MI-E and MAC for tracheostomy airway clearance should be 
strongly considered through tracheostomy to complement or 
replace deep suctioning. (Grade of recommendation 1C) 
5. Clean, as opposed to sterile, conditions are adequate for home 
secretion clearance and suctioning. (Consensus) 
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SECTION II. TRANSITION TO HOME (PATIENTS 
ADMITTED TO HOSPITAL)
Introduction
Although chronic respiratory failure and the consequent need for 
long-term ventilatory support can result from a variety of diagnoses, in 
all cases, there are constants to be addressed when transitioning to 
home (1). There are both medical and nonmedical factors that deter-
mine the suitability of a VAI to go home on ventilatory support (2-8). 
A comprehensive assessment must be performed by an interdisciplin-
ary health care team to provide the necessary training to make a suc-
cessful transition to home – ideally with a rehabilitative approach 
(4,9).
Key evidence
Prospective observational studies and retrospective reviews based on 
small numbers of patients comprise the evidence base for the recom-
mendations on the transition to home (10-12). The strength of the 
recommendations informing this section is primarily based on the 
consensus of the HMV committee. Current publications address dif-
ferent aspects of the factors influencing successful transition of VAIs 
to home. Randomized control studies in this topic are unlikely to be 
conducted.
Conclusion
The transition to home is a complex and demanding process for VAIs, 
and require highly sophisticated technology. Effective initiation and 
optimal monitoring of treatment are essential elements of successful 
HMV. The HMV committee recommends that an interdisciplinary 
team of health care professionals is of utmost importance for successful 
transition to home – provided that decisions are made under the 
leadership of a physician who is experienced in long-term ventilation. 
Commitment, motivation and preparation from patients’ families and 
caregivers are also crucial for a successful transition to HMV. Family 
preparation is especially important in the establishment of care at 
home for VAIs who are not fully independent.
Prospective users of HMV need to be advised that acquiring equip-
ment, learning how to use it and preparing the home environment can 
take a significant amount of time. Furthermore, the needs of the 
patient, family, caregivers and the home health care team must each 
be taken into consideration during this initial process. The interface of 
the VAI and the ventilator (invasive or noninvasive), for example, 
will greatly influence the complexity of individual care plans (13-15).
Many VAIs do not have the level of personal or third-party insur-
ance to cover the initial costs of the ventilator and associated respira-
tory equipment. In addition, if the equipment malfunctions or fails, 
they may not have the resources to repair or obtain replacement in a 
timely fashion, thus increasing the likelihood of a return to hospital. 
Therefore, it is strongly suggested that a publicly funded system to sup-
port VAIs in the community be available and include timely access to 
equipment, maintenance services and a structured, ongoing educa-
tional program. Such a program is also expected to facilitate the transi-
tion to home, thus reducing hospital days.
SECTION II. RECOMMENDATIONS
1. The candidate should be medically stable without constant or 
frequent monitoring, tests or treatment changes. (Consensus)
2. The candidate and family must be motivated (Consensus):
• VAIs must express interest in transitioning/living in the 
community.
• The family should express commitment to having the VAI 
live in the community. 
• The family is willing to provide support (physical, 
emotional and financial).
3. The candidate must have an adequate home setting 
(Consensus):
• Identifiable home to live in, suitable to the needs of the 
VAI. 
• Home is adaptable as necessary.
4. The candidate must have sufficient caregiver support 
(Consensus):
• Caregivers identified and committed to provide sufficient 
hours of care to meet the needs of the VAI.
• Available government-funded care hours identified.
5. The candidate must have access to adequate financial 
resources (Consensus):
• Sources of financial assistance identified and accessed.
• Sufficient financial resources available to meet projected 
costs.
6. The candidate must have access to equipment appropriate for 
the needs (Consensus):
• Appropriate equipment selected and ordered. 
• Sources for ongoing supplies identified.
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7. There must be comprehensive initial training, plus ongoing 
education and training for patient and caregivers once they 
are in the home setting (Consensus):
• Initial education organized to accommodate learning, practice 
and inclusion of caregivers in the care routine as early as 
possible.
8. The candidate must have access to health care support in the 
community (Consensus):
• Follow-up care available as appropriate (tracheotomy tube 
changes, ventilator reassessments and assessment of the 
ongoing effectiveness of the ventilatory support).
• Medical follow-up to allow for appropriate changes to the 
mode of ventilation (ie, from invasive to noninvasive and 
vice versa, from continuous to nocturnal and vice versa). 
• Professional services available postdischarge.
• A government-funded ventilatory service is necessary to 
provide appropriate access to equipment and respiratory care.
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SECTION III. HMV FOR PATIENTS WITH ALS
Introduction
ALS is a neurodegenerative disorder involving both upper and lower 
motor neurons that results in the progressive weakness of skeletal 
muscles. Death usually occurs as a result of progressive respiratory 
muscle involvement, with 50% of patients dying within three years of 
symptom onset (1). The rapid progression to death separates ALS from 
most other NMDs for which NIV and tracheostomy ventilation is 
considered. ALS is also distinct from other ventilated medical condi-
tions, including other NMDs, by virtue of having the poorest survival 
on ventilation (2). As a result, authors have tried to address the ques-
tion of benefit of NIV in this disease.
In reviewing the evidence, consideration was given to the type and 
magnitude of benefit of NIV in ALS, monitoring required in this 
population, and timing or parameters for initiation of ventilation to 
obtain any significant benefit. The committee also attempted to find 
evidence for the specific manner in which ventilation should be per-
formed in this population.
Key evidence
Compared with other disease groups, there is a relatively large volume 
of literature that attempts to answer the questions posed above. 
However, despite suggesting benefit for ventilation in ALS, the avail-
able information is not definitive and is of low quality in many instan-
ces. There is only a single RCT, and the remainder of the literature 
consists of prospective and retrospective studies or series. Control 
groups are present in many of the prospective studies; however, they 
often consist of historical controls, patients declining or unable to 
tolerate treatment, or patients with similar disease severity without 
respiratory involvement.
One small RCT (3), nine prospective studies (4-12) and six retro-
spective reviews (13-18) inform the question of benefit of home NIV 
or timing of initiation of NIV in patients with ALS. In these studies, 
outcomes of interest included survival, health-related QoL (HRQoL), 
pulmonary function, gas exchange, sleep parameters, cognition and 
timing of initiation of NIV.
One RCT (3), four prospective studies (4,5,8,12) and three retro-
spective reviews (15-17) informed the question of survival benefit 
with NIV. They all reported a survival benefit; however, the magni-
tude of the survival benefit was modest. Subset analysis of the bulbar-
predominant patients in the RCT (3) did not show a survival benefit 
in the patients with severe bulbar dysfunction.
Seven studies, including the single RCT, reported QoL measures 
(3,4,6,7-10). All showed improvement in QoL in some domains, with 
these improvements persisting in spite of disease progression. The 
improvement in QoL was still found in the more severe bulbar popula-
tion in the RCT, although gains were not as significant (3). Another 
study examined cognitive function before and after ventilation (6), 
and showed improvement following initiation of NIV that was 
assumed to be secondary to treatment of sleep disordered breathing.
Some studies identified other benefits, including a slowing of 
decline in VC (10,12,16) and improved arterial blood gases (ABGs) 
(6,9,19) following initiation of ventilation. Indications for the initia-
tion of ventilation in studies showing benefit have not been consist-
ent, making it difficult to answer the questions of how to monitor 
patients and when to initiate ventilation. Earlier literature focused on 
measures of lung function that predict daytime hypercapnia or a short 
time to death because these were frequently used criteria to initiate 
mechanical ventilation. More recently, the focus has been on pre-
dicting nocturnal hypoventilation to initiate ventilation earlier. A 
sitting VC of <50% of predicted was recognized as a prognostic factor 
predicting death in less than six to nine months (20-22). Sniff nasal 
pressure (SNP), a noninvasive measure of respiratory muscle strength, 
was shown to better predict daytime hypercapnia than VC and max-
imal inspiratory pressure (MIP) (23), and can be performed more reli-
ably than MIP in advanced disease, particularly when there is bulbar 
weakness. Bulbar weakness often leads to difficulty in maintaining an 
adequate oral seal and, hence, obtaining reliable measurements. An 
SNP of <40 cm was also found to correlate with nocturnal hypoxemia 
and a median survival of six months (24). MIP is also a sensitive test of 
muscle function and can be used late in the disease to predict survival, 
although it also requires the patient to be able to form a seal around a 
mouthpiece for reliable measurements. A reduction in VC on assuming 
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the supine position is frequently associated with the symptom of ortho-
pnea (25), and the percentage drop correlates with the lowest satura-
tion in rapid eye movement sleep (26). One author found a Borg 
dyspnea scale of ≥3 on assuming the supine position a useful predictor 
of an SNP ≤40 and impending respiratory failure (27). Symptom 
improvement was reported in four studies in which documented sleep 
disordered breathing was treated with NIV (17,20,28,29). Orthopnea 
is a frequent indication for initiation of ventilation in the studies 
reported (4,5,8,10,13,15). One study (10) showed that the greatest 
benefit and adherence occurred in patients who complained of ortho-
pnea. The same study suggested that patients treated for asymptomatic 
nocturnal hypoventilation were less compliant, although the numbers 
were very small.
Evidence is lacking to inform the questions of where ventilation 
should be initiated and how the initial and subsequent ventilator set-
tings should be chosen. Only eight of the 16 studies informing the 
question of benefit of NIV described how the ventilator settings were 
determined. In spite of demonstrating successful treatment, only one 
study (17) used polysomnography to determine settings, and only 
three studies (3,10,13) used nocturnal oximetry to evaluate settings 
after initiation. Seven of the eight studies that described methods for 
setting the initial ventilation (3,5,8-10,12,13) reported adjusting the 
ventilation to patient comfort and symptoms. Not all authors reported 
the type of bilevel parameter used (spontaneous versus spontaneous/
timed [S/T]). Of those reporting, however, all reported the S/T mode 
with which a back-up rate is provided. The remainder of the studies 
that did not use bilevel pressure ventilation used volume-cycled venti-
lation, which requires specification of a respiratory rate. Because cen-
tral apneas and hypoventilation figure prominently in previous 
descriptions of sleep disordered breathing in patients with ALS 
(17,20,28-32), a backup rate would be recommended if bilevel ventila-
tion is used.
Tracheostomy ventilation is an option if prolonged survival is 
desired and cannot be achieved with NIV. In a recent Canadian survey 
of ventilatory practices in ALS (33), it was estimated that only 1.5% 
of ALS patients receive this type of ventilation. Tracheostomy ventila-
tion is associated with a high burden of care and, although chosen by 
some, tracheostomy may result from an acute deterioration and intub-
ation when a personal directive is unavailable.
Following tracheostomy for acute respiratory failure, a recent 
Italian study (34) reported that none of the patients died in hospital; 
however, 70% were discharged completely ventilator dependent, and 
28% partially ventilator dependent. Only one patient was liberated 
from mechanical ventilation. None of the patients had their tracheos-
tomy removed. Bach (16) and Bach et al (35) described decannulation 
after tracheostomy in a select group of ALS patients with preserved bulbar 
function and the ability to generate an assisted PCF of >160 L/min. 
Despite these occasional reports and the possibility of an extended 
period of NIV after decannulation, tracheostomy will be required in 
the future because bulbar function deteriorates if patients choose inva-
sive ventilation in the hope of prolonged survival.
Since 2007, diaphragm pacing has been reported in 38 patients 
with ALS (36), and there is an ongoing trial targeting this therapy in 
100 ALS patients. The initial goal with this therapy was to reduce the 
rate of decline in lung function. The laparoscopic insertion of the 
electrodes into the diaphragm in patients with a forced vital capacity 
(FVC) of >50% predicted has been shown to be safe, with no mortality 
and low morbidity (37). Applied positive airway pressure (PAP) may 
still be required during pacing to avoid upper airway collapse. In the 
small number of ALS patients reported to date, there may be a slower 
rate of decline in lung function, which was extrapolated to a longer 
ventilator-free survival rate. Report of the larger series of ALS patients 
is pending; however, this technology is not yet approved for ALS 
patients in Canada.
The importance of airway clearance is highlighted in Section I 
(Airway Clearance). There have been studies conducted specifically 
in the ALS population, however, that warrant mention. One study 
investigated predictors of ineffective cough during chest infections in 
patients with stable ALS (38). They found that a Norris bulbar scale 
of <29 (normal function 39), PCF <4.25 L/s in stable ALS patients 
predicted ineffective cough with a chest infection and, therefore, sug-
gested that assisted clearance techniques be introduced when patients 
reach one or more of these thresholds. Another study in ALS patients 
(39) showed that PCF could be dramatically increased with various 
assisted-cough techniques, even in patients with bulbar dysfunction, a 
group in whom it has been challenging to achieve good clearance of airway 
mucus. Finally, a study assessing the efficacy of MI-E in stable ALS patients 
(40) also found that this technique could generate clinically effective PCF 
in all patients but those with very severe bulbar dysfunction.
Conclusion
The majority of the studies investigating outcomes of NIV use have 
been observational cohort studies, with only a single RCT to date. 
Although the evidence base is modest, it is relatively consistent in 
favour of benefit to patients able to tolerate NIV. In ALS patients, the 
survival benefit is modest compared with other diagnoses for which 
HMV is commonly recommended. The improvement in QoL, includ-
ing improvements in measures of daytime fatigue and sleepiness, seems 
to be a more relevant end point in this patient population. Sustained 
improvements in QoL were seen in most studies. Most importantly, 
there was no deterioration in QoL with NIV use apart from the 
expected changes in domains related to physical functioning second-
ary to increasing disability. Initiation of ventilation for symptomatic 
daytime hypercapnia or orthopnea secondary to muscle weakness 
seems clear. Earlier initiation for nocturnal hypoventilation with nor-
mal daytime PCO2 or based on higher FVC may be of benefit, but the 
evidence to date is limited.
SECTION III. RECOMMENDATIONS
1. Regular monitoring of ALS patients is advised from the time of 
diagnosis every two to six months and varies with anticipated 
rapidity of disease progression and should include the following:
• Symptom review to include orthopnea, dyspnea, poor sleep, 
excessive daytime sleepiness, poor concentration, morning 
headache. (Grade of recommendation 1C)
• Measurement of sitting FVC. (Grade of recommendation 1C)
• Measurement of one or more of the following: supine VC, 
SNP, PImax (MIP). (Grade of recommendation 1C)
• Measurement of ABGs or end tidal CO2 (ETCO2) when 
hypercapnia is suspected. (Grade of recommendation 1C)
• Nocturnal oximetry ± transcutaneous CO2 (tCO2) when 
symptomatic sleep disordered breathing is suspected. (Grade 
of recommendation 2C)
• Measurement of PCF. (Grade of recommendation 1C)
2. NIV should be offered to patients with any one of the following:
• Orthopnea (Grade of recommendation 1B)
• Daytime hypercapnia (Grade of recommendation 1B)
• Symptomatic sleep disordered breathing (Grade of 
recommendation 1C)
• FVC <50% predicted (Grade of recommendation 1C)
• SNP <40 cmH2O or PImax<40 cmH2O (Grade of 
recommendation 1C).
3. Ventilator settings should be adjusted for optimal patient 
comfort and improvement of symptoms. ABGs and/or 
nocturnal oximetry and/or polysomnography are not required, 
but may be helpful in some circumstances. (Grade of 
recommendation 1C)
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4. When bilevel pressure ventilators are used for NIV, a backup 
rate is recommended. (Grade of recommendation 1C)
5. Indicators of the effectiveness of ventilatory support should 
include symptom resolution, overnight oximetry and/or 
ETCO2. (Grade of recommendation 1C)
6. NIV should be considered the preferred option for 
ventilation even when ventilation is required 24 h per day. 
Elective tracheostomy ventilation may be considered, and is 
dependent on regional resources and careful discussion with 
the patient and caregivers. (Grade of recommendation 1C)
7. Long-term invasive ventilation can be offered after acute 
respiratory failure requiring invasive ventilation, if the 
patient and caregivers fully understand the consequences 
and appropriate support is available (Section II. Transition 
to Home). (Grade of recommendation 2C)
8. Lung volume recruitment manoeuvres should be introduced 
with declining VC (Section I. Airway Clearance). (Grade 
of recommendation 1C)
9. Methods to assist secretion clearance should be initiated 
when PCF is <4.25 L/s or the Norris bulbar score is <29. 
(Grade of recommendation 1C)
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SECTION IV. HMV FOR PATIENTS WITH CHS
Introduction
Patients with CHS present with varying degrees of severity. Patients are 
known to have normal lung function and respiratory muscle strength. The 
problem resides in the development of adequate neural drive from the 
central nervous system, to maintain a normal PCO2. Severe congenital-
CHS (C-CHS) presents at birth with profound hypoventilation that 
requires continuous invasive ventilatory support. Alternatively, adults 
presenting in later life, for example with late-onset CHS (LO-CHS) or an 
acquired form of CHS, may only have nocturnal hypercapnia. Eventually, 
these patients tend to progress to diurnal hypercapnia with daytime symp-
toms. These daytime symptoms commonly include morning headaches, 
sleepiness and confusion, and dictate the need for nocturnal ventilatory 
support. CHS can be acquired due to brainstem disease, for example, or 
from a stroke or tumour. When brainstem disease is excluded by magnetic 
resonance imaging, genetic analysis is indicated (1,2). The presence of a 
mutation in the PHOX2B gene is identified in most cases and confirms 
the genetic nature of this condition. The mode of inheritance is auto-
somal dominant. This mutation is usually a polyalanine expansion that 
causes more severe hypoventilation as the expansion lengthens. First-
degree relatives of affected individuals should be offered genetic testing 
and screened for hypoventilation because they may also carry the muta-
tion and should be counselled appropriately.
Key evidence
The literature search revealed 10 articles reporting on the manage-
ment of CHS patients. The experience reported is largely based on 
case series with a focus on C-CHS (3-8). Due to the rarity of CHS, 
there is little evidence to support an optimal approach to manage-
ment; thus, recommendations informing this section are primarily 
based on consensus of the HMV committee and a recent American 
Thoracic Society statement on C-CHS (9).
Conclusion
In the adult population, there are little data regarding long-term 
follow-up, with most reports focusing on describing the causes of 
acquired CHS. In this setting, nocturnal NIV is often all that is 
required. In the pediatric population, C-CHS can be quite profound at 
birth, requiring continuous invasive ventilatory support; however, as 
the child matures, breathing may require support at night only 
(7,8,10). The options for ventilatory support include positive pressure 
ventilation (PPV) via tracheostomy, NIV or diaphragm pacing 
(10,11,12). There is a preference for NIV or diaphragm pacing as the 
child matures, with the aim of decannulation. In the less common 
situation in which 24 h ventilation is required, diaphragm pacing 
allows for increased mobility during the day and, in some cases, NIV 
can suffice at night with the potential for decannulation. Alternatively, 
NIV may be adequate for 24 h ventilatory support when the patient is 
at the age to be capable of adopting it. Transition clinics for children 
are important in providing a care plan, particularly for the more com-
plicated patients with C-CHS as they move into adulthood.
SECTION IV. RECOMMENDATIONS
1. The diagnosis of CHS in adults with less severe 
hypoventilation is best made by standard polysomnography 
with the addition of tCO2 or early morning arterial PCO2.
(Grade of recommendation 1C)
2. Once the diagnosis of CHS is established, it is strongly 
recommended that acquired causes should be excluded by 
magnetic resonance imaging of the brainstem. (Grade of 
recommendation 1C)
3. Patients with CHS and no known acquired cause should 
undergo genetic screening for the PHOX2B gene mutation. 
(Grade of recommendation 1C)
4. For patients confirmed to harbour the PHOX2B mutation, first-
degree relatives should be offered genetic testing and screening 
for hypoventilation. (Grade of recommendation 1C)
5. CHS patients who require only nocturnal ventilatory support 
may be managed by NIV with a backup rate or diaphragmatic 
pacing. (Grade of recommendation 1C)
6. Severe CHS, mainly seen in C-CHS, requires continuous 
invasive ventilatory support, but daytime diaphragmatic 
pacing can markedly improve mobility and, as the child 
matures, NIV may suffice. (Grade of recommendation 1C)
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SECTION V. LONG-TERM NONINVASIVE PPV IN 
PATIENTS WITH STABLE COPD
In this section, noninvasive PPV (NIPPV) will replace ‘NIV’ because 
the term is commonly used in the COPD population.
Introduction
The goal of COPD treatment is to slow disease progression, reduce the 
frequency of exacerbations, alleviate dyspnea, improve exercise toler-
ance, improve health status and reduce mortality (1). Although sev-
eral physiological outcomes such as ABGs, work of breathing and 
respiratory muscle strength can be improved by long-term mechanical 
ventilation, the clinical relevance of these outcomes from the perspec-
tive of the patient and/or health care system is uncertain.
Recommendations for the use of NIPPV in COPD will thus be based 
on the results of clinical trials that have assessed the impact of NIPPV 
on patient-oriented clinical outcomes.
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Key evidence
Seven RCTs (2-8) comprise the evidence base regarding the role of 
long-term NIPPV in patients with stable COPD. Recommendations 
informing this section are based on evidence from these RCTs and the 
consensus of the HMV expert panel.
Conducting a clinical trial investigating the efficacy of long-term 
NIPPV in patients with COPD is challenging. By definition, patients 
involved in these trials suffer from advanced chronic respiratory failure 
and, in some instances, from preterminal disease. A high dropout rate and 
a multitude of adverse events are, therefore, expected during such a trial. 
One problem in trying to interpret the current literature is the heterogen-
eity of the study population and the difference in the degree of ventilatory 
support among studies. Studies were either very small (2-4) or the investi-
gators were unable to meet the predefined sample size to ensure sufficient 
statistical power to address the outcomes of interest (5,7,8).
Our interpretation is that the current literature does not support 
the use of NIPPV in stable patients with COPD with chronic hyper-
capnic respiratory failure. The dyspnea data are difficult to interpret 
considering the different dyspnea scales that were used in the different 
trials. In one study, the reduction in Borg dyspnea score was statistic-
ally significant and probably clinically significant, with a reduction 
in one unit occurring in the NIPPV group compared with no change 
in the control group (5). In another study (6), a 0.6 point difference 
in the Medical Research Council dyspnea score in favour of NIPPV 
was reported. The dyspnea data can probably be viewed as positive, 
although of modest magnitude and uncertain clinical importance. 
The impact of NIPPV on HRQoL data was assessed in four studies 
that reached different conclusions on this issue (3,6-8). Although 
NIPPV may improve HRQoL as assessed by St George’s Respiratory 
Questionnaire (SGRQ) or by the Chronic Respiratory Questionnaire 
when associated with long-term oxygen therapy (LTOT) (3) or 
rehabilitation (7), the largest studies reported no improvement in 
SGRQ scores (6,8). Using a questionnaire specifically designed to 
assess QoL in respiratory failure, evidence supporting improved QoL 
has been reported (6,7). In contrast, one study suggested that QoL may 
deteriorate with NIPPV (8). However, the clinical interpretation of this 
questionnaire is uncertain. Overall, it is difficult to draw a clear conclu-
sion on the impact of NIPPV on HRQoL from the published evidence.
The impact of NIPPV on exercise tolerance, as assessed by 6 min 
walk distance, and on sleep quality is inconclusive (3,4,6). The initia-
tion of long-term NIPPV in addition to oxygen, was not associated 
with a reduced risk of hospitalization during long-term follow-up 
(12 to 24 months) when compared with oxygen alone (5,6). Finally, 
NIPPV did not prolong survival in two studies involving patients with 
stable COPD (5,6). A survival advantage of NIPPV when used in 
conjunction with LTOT compared with LTOT alone has been 
reported (8). The biological plausibility of this study is questionable 
because the level of positive pressure applied was low and failed to 
improved daytime PaCO2.
Despite the limitations and the lack of clear supportive evidence, 
long-term NIPPV is widely used in patients with COPD. In some 
countries, COPD is one of the most rapidly rising indications for long-
term ventilatory support (9). This is not trivial considering the large 
COPD population and the potential economic impact associated with 
long-term NIPPV in this population. Some experts would consider 
long-term NIPPV in patients with COPD and chronic hypercapnia 
experiencing repeated bouts of acute respiratory failure requiring 
ventilatory support in the hospital. The hope here is that this will 
reduce health care use (10). Given the lack of certainty about the 
efficacy of NIPPV in this patient population, isolated PaCO2 eleva-
tion is unlikely to represent a useful clinical indication (11).
Obesity, obstructive sleep apnea (OSA) and COPD are common 
medical conditions; their concomitant presence in the same individ-
ual is, therefore, not unusual. The coexistence of OSA and COPD is 
often coined the ‘overlap syndrome’ (12). Obesity and sleep apnea 
may lead to hypercapnic respiratory failure when associated with 
airflow obstruction. This situation should be suspected when the 
degree of airflow obstruction is milder (forced expiratory volume in 1 s 
[FEV1] >40% predicted) than usually seen in a typical case of hyper-
capnic respiratory failure that is solely due to advanced COPD. The 
overlap syndrome should be differentiated from chronic hypercapnic 
respiratory failure due to advanced COPD because these two condi-
tions may well require different treatment. NIPPV is often used in 
this setting and discussed in more detail in Section VII.
Conclusion
The current literature of RCTs does not provide convincing evidence 
that NIPPV is effective in improving patient-oriented clinical out-
comes such as dyspnea, exercise tolerance, QoL, hospitalization and 
survival in COPD. Long-term NIPPV may be appropriate in carefully 
selected patients when COPD is accompanied by chronic hypercapnia 
and repeated bouts of acute respiratory failure requiring ventilatory 
support in the hospital, with the expectation that this will reduce 
health care use.
SECTION V. RECOMMENDATIONS
1. The use of long-term NIPPV cannot be widely recommended 
in patients with stable COPD. (Grade of recommendation 1B)
2. Long-term NIPPV in COPD should only be considered on an 
individual basis. One subgroup of patients with COPD in 
which long-term NIPPV could be considered are those with 
severe hypercapnia (PaCO2 >55 mmHg) experiencing repeated 
episodes of acute hypercapnic respiratory failure that require 
in-hospital ventilatory support. However, definitive proof of 
efficacy of long-term NIPPV in these patients will need to 
await future studies. (Grade of recommendation 2C)
3. The overlap syndrome, and concomitant COPD and OSA 
syndrome, should be differentiated from chronic respiratory 
failure that is solely due to advanced COPD. (Grade of 
recommendation 1C)
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SECTION VI. HMV IN PATIENTS WITH 
KYPHOSCOLIOSIS
Introduction
Kyphoscoliosis is a well-recognized cause of respiratory failure (1). 
The most common cause is idiopathic scoliosis, which begins in 
childhood. Kyphoscoliosis may also occur secondary to other disor-
ders including NMD, vertebral disease, connective tissue abnormal-
ities and thoracoplasty (2). The degree of thoracic spinal deformity is 
the most important risk factor for the eventual development of respira-
tory failure. Surgically untreated patients with a VC of <45% of pre-
dicted values and a scoliotic angle >110% are at particular risk of 
respiratory failure (3). This risk is elevated if NMD or coexistent lung 
disease is present. Once respiratory failure or corpulmonale develops, 
life expectancy with conservative therapy is poor. Up to 50% of 
untreated patients can be expected to die within one to two years 
without the initiation of oxygen or ventilatory support (1).
Key evidence
A total of 12 studies were identified informing the primary outcomes of 
interest on the role of HMV in patients with kyphoscoliosis (4-15). An 
additional study reporting on outcomes of NIV in post-tuberculosis 
patients with the combination of respiratory failure and chest wall deform-
ity is relevant (16). Support for the use of NIV in kyphoscoliosis was 
initially established by the publication of several retrospective single 
cohort studies demonstrating improved survival compared with historical 
mortality (4-8). Subsequently, two large observational registries have dir-
ectly compared survival between patients managed by LTOT or home 
ventilation (10-11), and both have demonstrated that home ventilation 
has a significant survival advantage. A smaller comparative study (12) 
also found similar results. Several smaller studies have confirmed earlier 
reports of improved gas exchange and indicate that home ventilation may 
improve some parameters of lung function, exercise endurance and QoL 
(13-15). Recommendations informing this section are based on the lim-
ited evidence and the consensus of the HMV committee.
Conclusion
Evidence is lacking to support the initiation of NIV on the basis of pul-
monary function alone – indeed, there are many factors that must be 
considered. Patients with kyphoscoliosis who present with a VC of <50% 
predicted value can survive for many years before respiratory failure 
develops (3). Follow-up of patients presenting with acute hypoxic, hyper-
capnic respiratory failure caused by kyphoscoliosis has demonstrated that 
some patients can survive for years on oxygen therapy without ventilation 
(17). If oxygen therapy can relieve hypoxemia in patients with respiratory 
failure secondary to kyphoscoliosis without the development of hypercap-
nia, oxygen therapy alone can be considered; however, over time, mon-
itoring for the development of CO2 retention is critical, and the addition 
of ventilatory support may be required (9). Most patients with established 
chronic hypercapnic respiratory failure caused by kyphoscoliosis should be 
offered nocturnal NIV (4-16).
SECTION VI. RECOMMENDATIONS
1. Patients with kyphoscoliosis should undergo periodical spirometry 
testing, and if FVC is <50%, ongoing review, assessing for evidence 
of hypercapnic respiratory failure should be instituted. (Grade of 
recommendation 1C)
2. Long-term nocturnal NIV should be offered to all patients with 
kyphoscoliosis who have developed chronic hypercapnic respiratory 
failure. (Grade of recommendation 1B)
3. Patients with hypoxemia but without hypercapnia may be managed 
cautiously with oxygen therapy alone while monitoring for 
development of hypercapnia. (Grade of recommendation 1C)
4. Oxygen therapy could be added to NIV, if considered necessary, for 
unresponsive oxygen desaturation. (Grade of recommendation 1C)
5. Methods to assist secretion clearance should be initiated when peak 
cough flow is <270 L/min (Section I. Airway Clearance) (Grade of 
recommendation 1C)
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SECTION VII. HMV FOR PATIENTS WITH OHS
Introduction
OHS is best characterized as daytime hypercapnia not due to respiratory 
or NMD, and accompanied by obesity and sleep disordered breathing 
(1). For the purpose of this review, OHS is defined as follows:
1. Obesity (body mass index [BMI] >30 kg/m2).
2. Daytime hypercapnia (PaCO2 >45 mmHg).
3. Absence of other causes of hypoventilation.
Sleep disordered breathing is very common among OHS patients, 
although not necessarily a part of the definition. Most OHS patients 
(80% to 90%) also suffer from OSA, while hypoventilation without 
OSA and central apnea are less common (2).
The exact prevalence of OHS in the general population is not 
known. The prevalence of OHS in patients with OSA has been 
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estimated to be between 20% and 30% (3). In a large French study of 
1141 adults with OSA (4), daytime hypercapnia was present in 9.8% 
of patients with a BMI >30 kg/m2 and <40 kg/m2, and in 23.6% with a 
BMI >40 kg/m2 (4). Despite this, OHS still remains under-recognized. 
In one study of obese patients (BMI >35 kg/m2) admitted to the hos-
pital, 23% of OHS patients were correctly diagnosed and only 13% 
received treatment for OHS on discharge (5).
Because the rates of obesity are rising rapidly, the prevalence of 
OHS is likely to increase. It is estimated that the prevalence of mor-
bid obesity (BMI >40 kg/m2) in the United States has quadrupled 
between 1986 and 2000 (6). Similar trends are evident in Canada: 
between 1979 and 2004, the obesity rate in Canadian adults has 
increased from 13.8% to 23.1% while the percentage of Canadian 
adults with class III obesity has tripled (0.9% to 2.7%) (7). It is, 
therefore, not surprising that OHS is one of the most common rea-
sons to initiate NIV. In a recent study of 1526 adults who started 
HMV in Sweden between 1996 and 2005 (8), OHS constituted the 
largest group (n=422 [28%]). In another study (9), 59 of 111 patients 
who received nocturnal HMV in New Zealand had OHS. A review 
of all HMV prescriptions in a Swedish registry between 1996 and 
2002 (10) revealed that the OHS group had the highest increase (8% 
to 17%) of all ventilated patients.
The majority of OHS subjects present with symptoms of OSA, but 
may also experience headaches, dyspnea and limb edema. OHS sub-
jects have been shown to have increased mortality, hospitalization 
rates, high prevalence of pulmonary hypertension and increased use of 
health care resources. Decreased HRQoL, vigilance and CO2 sensitiv-
ity have also been demonstrated. When compared with a BMI-
matched population, OHS patients exhibit high rates of congestive 
heart failure, angina and pulmonary hypertension (11). Compared 
with eucapnic patients with OSA, patients with OHS have a lower 
QoL, experience more somnolence, incur higher health care expenses 
and greater risk of pulmonary hypertension (12). OHS patients have 
higher rates of intensive care unit admissions and a greater need for 
invasive mechanical ventilation (4).
Key evidence
The literature search identified 11 studies (11,13-22) of HMV involv-
ing 378 OHS patients treated with bilevel or volume-cycled ventila-
tion (n=274) or continuous PAP (CPAP) (n=104). The majority of 
studies were prospective cohort or retrospective in design, had differ-
ent enrollment criteria, used different modes of ventilation and had 
different places of initiation of therapy, variable follow-up and dropout 
rates. It must be emphasized that CPAP is not a ventilatory device and 
is not routinely used to treat hypoventilation; however, it is included 
in the present review because there are studies demonstrating its effi-
cacy in a subset of OHS patients.
Conclusion
The existing evidence indicates that HMV using NIV is effective in the 
majority of OHS patients and results in significant improvement in 
symptoms of somnolence, dyspnea, edema and sleep quality, as well as 
improvements in gas exchange, sleep architecture and HRQoL. While 
there is still uncertainty about the optimal ventilatory mode in OHS, 
and because only one RCT compared CPAP and bilevel PAP, the 
existing evidence shows that bilevel therapy is effective in the majority 
of OHS cases, while CPAP is effective in a subgroup of OHS subjects 
with mild OHS and OSA. Newer ventilatory support modalities with 
tidal volume assurance have shown promise; however, additional long-
term studies are required.
SECTION VII. RECOMMENDATIONS
1. NIV is the treatment of choice for OHS. (Grade of 
recommendation 1A)
2. In patients with OHS who have a minor degree of nocturnal 
desaturation and no nocturnal rise in PaCO2, CPAP is a 
reasonable initial therapy provided that follow-up is arranged 
within one to three months to evaluate response to therapy. 
(Grade of recommendation 1B)
3. Under circumstances when access to more than one device 
(bilevel PAP or CPAP) is limited, bilevel therapy is 
recommended. (Grade of recommendation 1C)
4. In patients with OHS who experience significant nocturnal 
desaturation or a nocturnal increase in PaCO2, bilevel PAP 
remains the therapy of choice. (Grade of recommendation 1B)
5. Polysomnography is useful for titrating and confirming efficacy 
of bilevel pressures. (Grade of recommendation 1C)
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SECTION VIII. HMV IN PERSONS WITH SCIs
Introduction
Respiratory complications continue to be one of the leading causes of 
morbidity and mortality in individuals with SCI, despite advances in 
SCI care, for which acute and long-term mortality rates have declined 
(1). Although research has suggested dramatic improvement in sur-
vival for individuals with SCI over the past few decades, this is only 
in the critical first few years postinjury (2), and the life expectancies 
of ventilator-dependent patients with SCI have not improved (1). 
The degree of respiratory impairment in individuals with SCI depends 
on the level and grade of injury. Complete high cervical cord lesions 
are associated with the greatest respiratory muscle dysfunction. With 
injuries affecting innervation of the abdominal muscles, the ability to 
cough and clear secretions is compromised, and strategies for manage-
ment of airway secretions and prevention/treatment of atelectasis and 
pneumonia must be implemented.
Most patients acutely supported by a ventilator will recover spon-
taneous breathing (3); however, approximately 5% of individuals 
require ongoing ventilatory support (4). Respiratory function remains 
impaired in individuals with tetraplegia, and assisted ventilation may 
be indicated in patients with chronic injuries.
Key evidence
There are no RCTs involving mechanical ventilation in patients with 
SCI. Evidence consists of retrospective reviews and small case series, 
supported by consensus of the HMV expert panel.
In a survival analysis study, Shavelle et al (5) identified that trends 
in improved survival otherwise observed in SCI were not seen among 
ventilator-dependent SCI patients surviving the first critical years, and 
that ventilator dependency remained an independent risk factor for 
mortality. Respiratory complications were the leading cause of mortal-
ity, accounting for 31% of deaths (5). DeVivo and Ivie (6) identified 
significantly reduced life expectancy for ventilator-dependent individ-
uals following spinal cord injury, even when controlled for age, sex and 
race. In adults, ventilator dependency is the strongest negative pre-
dictor of survival during the first year after hospital discharge.
Three surveys of VAIs with high tetraplegia (total n=75 VAIs in 
three studies [7-9]) suggested that QoL and life satisfaction are high. 
Recently, authors have reported improved QoL indicators for individ-
uals who have been successfully implanted with phrenic nerve or dia-
phragmatic pacing (currently a research tool not yet approved in 
Canada), enabling ventilator-free breathing after long-term ventilator 
dependency (10,11). Pacing is associated with better power-chair man-
agement, increased hospital discharge, phonation and sense of smell.
For patients who require assisted ventilation, noninvasive 
approaches are associated with fewer complications than invasive 
ventilation, as described in three retrospective studies. Noninvasive 
approaches require reasonably intact bulbar musculature and alert 
mental status. Bach and Alba (14) described a monitored sequence of 
manual and mechanical coughing techniques, progressive tracheos-
tomy cuff deflation and adjustment of ventilator volumes in success-
fully converting 23 of 25 high tetraplegia patients from invasive to 
noninvasive support.
Retrospective reviews by Peterson et al (15) describe ventilator 
weaning protocols that compared intermittent mandatory ventilation 
with a progressive ventilator-free breathing (PVFB) approach, in 
which PVFB demonstrated a higher success rate. PVFB should be con-
sidered for appropriate patients with tetraplegia who are dependent on 
ventilation. There is greater support, albeit few studies, for PVFB than 
synchronized intermittent mandatory ventilation (15).
Alteration of pulmonary function and respiratory complications 
are a major cause of both morbidity and mortality in patients with SCI. 
There are no studies to provide direction for the long-term manage-
ment of respiratory dysfunction in persons with SCI. Patients at risk 
for impaired airway clearance (ie, PCFs <270 L/min) are encouraged 
to use LVR and preventive airway clearance strategies. Individuals 
with SCIs remain at risk for the development of sleep disordered 
breathing and those with higher injuries for respiratory failure. As 
such, regular follow-up every six to 12 months is recommended with a 
review of respiratory function, nocturnal gas exchange and any symp-
toms that would indicate respiratory compromise. Consideration 
should be given to initiation of NIV in such individuals. In stable 
patients identified with uncomplicated OSA, CPAP therapy alone 
may be all that is required with regular follow-up to exclude the 
development of respiratory failure, which would require PPV.
Conclusion
Ventilator dependency remains a negative predictor for survival following 
SCI, and invasive ventilation is associated with increased complications. 
Attempts to wean from ventilation should be considered whenever pos-
sible. Limited evidence suggests progressive ventilator-free breathing is 
more successful than intermittent mandatory ventilation. When ventila-
tion is required, NIV has been demonstrated to be associated with fewer 
complications. Patients requiring home ventilation report good QoL and 
well-being, with recent case series (10,11) finding improved QoL with 
diaphragmatic and phrenic nerve pacing options over ventilator depend-
ence. Although there are no trials in SCI to inform on long-term manage-
ment, expert consensus supports lifelong management of airway clearance 
and monitoring of potential needs for ventilatory support.
SECTION VIII. RECOMMENDATIONS
1. Protocols for weaning with PVFB should be considered for 
appropriate patients with tetraplegia who are dependent on 
ventilation. (Grade of recommendation 1C)  
2. Each patient must be individually evaluated for the need for 
long-term ventilation either acutely or in follow-up. 
Noninvasive support is preferable to invasive ventilation. 
(Grade of recommendation 1C)
3. Phrenic nerve pacing is recommended in selected individuals as 
an alternative to PPV alone. (Grade of recommendation 2C)
4. Regular airway clearance techniques (LVR, MAC and MI-E), 
clinical assessment and ongoing monitoring of pulmonary 
function is recommended to ensure adequate airway clearance. 
(Grade of recommendation 1C)
5. In the long term, individuals with SCI require regular 
monitoring to identify the development of sleep disordered 
breathing or respiratory failure and evaluate the need for NIV. 
(Consensus)
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SECTION IX. HMV FOR PATIENTS WITH DMD
Introduction
DMD occurs in approximately one in 3500 live male births. The dis-
ease is caused by mutations in the dystrophin gene, and leads to wide-
spread muscle fibre necrosis along with fibrosis and fatty cell infiltration 
of muscle including the respiratory muscles. Becker MD is a less preva-
lent and more slowly progressive form of the disease, in which aberrant 
but partially functional forms of dystrophin are expressed in muscle. In 
DMD patients, nocturnal or full-time home ventilation has been used 
for 25 to 30 years, but has only come into frequent use since the 
1990s.
Key evidence
In the majority of the studies selected for inclusion and analysis, the 
subject population consisted solely of DMD patients, although some 
studies containing a mixed population of NMDs were also included 
when there was a subgroup analysis of DMD patients, or when the data 
were deemed to be especially relevant and investigations specific to 
the DMD population were lacking. The studies addressed one or more 
clinical outcomes including survival, gas exchange (including during 
sleep) and pulmonary function, QoL and hospitalizations, and mode as 
well as timing of initiation for home ventilation.
Although the early experience with mechanical ventilation in 
DMD patients mostly involved the use of negative pressure devices, 
these have been largely abandoned in routine clinical practice due to 
problems of upper airway obstruction during sleep (1) as well as cum-
bersome application. Therefore, the studies included in this analysis 
are mostly limited to those examining the effects of PPV.
Conclusion
Despite limitations including small numbers of controlled studies 
specific to the influence of long-term mechanical ventilation on sur-
vival in DMD patients, as well as studies including patients with a 
heterogeneous group of NMDs or chest wall diseases, strong inferences 
regarding the benefits of long-term mechanical ventilation in DMD 
patients have been drawn from the literature. Among these are the 
significant improvements in survival that have coincided with the 
period during which NIPPV has come into more frequent use (2-6). 
Especially notable is that the survival benefit may partially be related 
to other improvements in the care of DMD patients, perhaps due in 
part, to improved management of the associated cardiomyopathy.
Pulmonary function should be monitored at least yearly, and 
patients carefully questioned about symptoms suggestive of nocturnal 
hypoventilation. The frequency should increase with progression of 
the disease because once VC falls to <40% predicted, patients are at 
significant risk for the development of nocturnal hypercapnia (7-9), 
followed within one to two years by clinical deterioration (10). 
Although full polysomnography with CO2 monitoring is generally 
preferred to distinguish upper airway obstructive events from hypo-
ventilation, and to confirm the occurrence of rapid eye movement 
sleep, we recognize that this may not be readily available and can also 
represent a significant burden for some patients. Depending on the 
specific circumstances and logistical constraints, alternative forms of 
respiratory monitoring during sleep (ideally including both oximetry 
and CO2 measurements) can also be used.
The available evidence strongly suggests that once diurnal hyper-
capnia has developed, QoL is reduced (10,11) and the risk of mortality 
within one year is high without ventilatory support (12). Under these 
conditions, nocturnal NIV can be effective in helping to improve 
daytime symptoms and reduce the degree of diurnal hypercapnia dur-
ing spontaneous breathing (9,12-14). In addition, failure to correct 
isolated nocturnal hypoventilation (equivalent to tCO2 >50 mmHg), 
even in asymptomatic patients, was shown to be a harbinger of clinical 
deterioration within a relatively short time period in one randomized 
study of patients with a mixed group of NMDs (10). At minimum, very 
close follow-up is needed in asymptomatic DMD patients with isolated 
nocturnal hypercapnia because it appears that many such patients 
could become symptomatic and require NIV within the next one to 
two years. In addition, we believe that nocturnal NIV should be 
offered to DMD patients if major hypoxemia during sleep has been 
documented, even when patients are asymptomatic.
If NIV must be extended beyond the night to include a substan-
tial period of daytime ventilatory support for relief of symptoms and 
maintenance of acceptable blood gases, strong consideration should be 
given to the avoidance of invasive tracheostomy in favour of mouth-
piece ventilation; depending on local logistical considerations, patient 
preference, and other factors such as bulbar and cognitive function, 
should be considered because these may preclude the use of mouthpiece 
ventilation.
Airway clearance strategies are critical to the success of NIV in 
patients with DMD and should be directed at achieving PCFs ≥270 L/min 
using LVR and MAC techniques as required. MI-E should be con-
sidered for those unable to obtain a PCF of 270 L/min (15).
SECTION IX. RECOMMENDATIONS
For monitoring
1. Carefully question and educate patients to report symptoms 
consistent with hypoventilation, including disturbed sleep, 
excessive daytime sleepiness, morning headache and weight 
loss. (Grade of recommendation 1C) 
2. Measure VC, MIP, maximal expiratory pressure, PCF and 
awake oxyhemoglobin saturation by pulse oximetry at least 
yearly; if VC <40% predicted, also monitor awake CO2 
tension by noninvasive methods or ABG analysis. (Grade of 
recommendation 1C) 
3. Perform an evaluation of ventilation during sleep if there are 
symptoms consistent with nocturnal hypoventilation or other 
forms of sleep disordered breathing (Grade of 
recommendation 1C).  
4. In the absence of such symptoms, periodic screening for sleep 
disordered breathing should also be considered once FEV1 or 
FVC is <40% predicted. (Grade of recommendation 1C) 
For treatment
1. Offer nocturnal NIV to patients with diurnal hypercapnia 
(daytime arterial PCO2 >45 mmHg), or when there is 
documented nocturnal hypercapnia and the presence of 
symptoms consistent with hypoventilation. (Grade of 
recommendation 1B)
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2. Institution of NIV during sleep should be offered to patients 
demonstrating a major degree of nocturnal hypoxemia, even if 
asymptomatic. (Grade of recommendation 2C) 
3. When bilevel ventilation is used, backup respiratory rates are 
recommended during sleep while on NIV to reduce the work 
of breathing associated with breath initiation. (Grade of 
recommendation 1C)
4. Individualize the decision about the transition from nocturnal 
NIV to daytime ventilation by carefully evaluating patient 
factors (symptoms, bulbar involvement, patient preference, 
etc) and available resources. In patients requiring daytime 
ventilation, strongly consider mouthpiece ventilation as an 
alternative to invasive tracheostomy. (Grade of 
recommendation 1B)
5. Lung volume recruitment manoeuvres should be introduced 
with declining VC. (Section I. Airway Clearance). (Grade of 
recommendation 1C)
6. Methods to assist secretion clearance should be initiated when 
PCF <270 L/min. (Section 1. Airway Clearance). (Grade of 
recommendation 1C)
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SECTION X. HMV FOR PATIENTS WITH OTHER  
MDs AND MYOPATHIES
Introduction
Myopathies and MDs represent a large group of diseases with differ-
ent modes of inheritance and different clinical features. Many 
myopathies and MDs are eventually complicated by respiratory 
failure and death (1,2). Causes of respiratory failure may include 
general respiratory muscle weakness occurring together with limb 
weakness as in limb girdle dystrophy. There may be selective dia-
phragm involvement as in facioscapulohumeral dystrophy or acid 
maltase deficiency. These conditions, with predominant diaphragm 
weakness, would be best assessed by measurement of supine as well 
as sitting VC. There may be associated skeletal dysmorphism-like 
pectusexcavatum and kyphoscoliosis as in Emery-Dreifuss muscular 
dystrophy. There may be impairments of central drive contributing 
to alveolar hypoventilation as in myotonic dystrophy. There may 
be coexisting interstitial pulmonary involvement leading to fibrosis 
in the inflammatory myopathies such as polymyositis and dermato-
myositis. Eventually, consideration must be given to long-term 
ventilatory support for patients suffering from these diseases who 
develop respiratory failure.
Key evidence
There are few studies (3-6) analyzing long-term ventilatory support 
for respiratory failure in specific myopathies and MDs other than 
DMD. MDs and myopathies are often mixed with other NMDs and 
chest wall disorders in most studies (7-10). Moreover, patients with 
these diseases often represent only a small fraction of cases 
included.
The general indication for long-term ventilatory support is the 
presence of daytime hypercapnia. Application of nocturnal NIV 
when these individuals become hypercapnic during the day prolongs 
survival, improves nocturnal and diurnal ABG tensions, normalizes 
sleep patterns and enhances HRQoL.
One RCT concluded that nocturnal hypoventilation without 
daytime hypercapnia is also a valid indication for HMV in patients 
with NMDs and chest wall disorders (8). These patients are likely to 
deteriorate with the development of daytime hypercapnia and/or 
progressive symptoms within two years as was seen in the control 
group. In this study, 11 of 48 patients had MDs or myopathies.
Another study (5) reported relationships between nocturnal res-
piratory variables and daytime lung function to identify potential 
patients with such nocturnal hypoventilation without reliance on 
expensive and frequently unavailable tests such as polysomnography. 
Of the 42 patients with NMD, 30 of 42 had MDs and myopathies. 
The authors concluded that bedside spirometry testing at six- to 
12-month intervals provided a low cost, reproducible way to deter-
mine which patients were at risk. Patients with VC >60% are 
unlikely to have any nocturnal hypoventilation, indicating good 
respiratory reserve and minimal risk of respiratory complications. 
Those with VC <60% were more likely to have nocturnal hypoventi-
lation, indicating reduced respiratory reserve and the potential need 
for polysomnography or alternative nocturnal monitoring. Those 
with VC <40% commonly demonstrated diurnal hypercapnia.
Conclusion
Based on recommendations made for other groups of NMD, the 
opinion of the expert panel and a small number of studies investigat-
ing home ventilation that included patients with MDs and myop-
athies, long-term ventilatory support for these patients is 
recommended when there is daytime hypercapnia or symptoms and 
signs of nocturnal hypoventilation. Periodic spirometry testing will 
help to identify patients as being of lesser or greater risk of respiratory 
failure. As for other chronic NMDs, the frequency of follow-up 
should be at least every six to 12 months, but is also determined by 
the rapidity of disease progression.
McKim et al
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SECTION X. RECOMMENDATIONS
1. Obtain periodic clinical assessment and spirometry at six- to 
12-month intervals, including sitting (plus supine if 
diaphragmatic weakness is suspected) spirometric testing. 
(Grade of recommendation 1C)
2. Consider monitoring for sleep disordered breathing in patients 
with VC <60%. (Grade of recommendation 1C)
3. Consider ABGs or nocturnal measure of CO2 in patients 
with VC <40% to exclude hypercapnia. (Grade of 
recommendation 1C)
4. NIV should be offered when there is daytime hypercapnia or 
symptomatic nocturnal hypoventilation. (Grade of 
recommendation 1C)
5. Assess airway clearance ability with PCFs and implement 
cough-assistance strategies (Section I. Airway Clearance). 
(Grade of recommendation 1C)
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SECTION XI. HMV FOR PATIENTS WITH MYOTONIC 
DYSTROPHY (SMD) 
Introduction
Myopathies and MDs represent a large group of diseases. Dystrophia 
myotonica (DM) (also known as myotonic dystrophy or Steinert’s 
disease) is of special interest because of its relatively high incidence in 
Canada and even more so in Quebec. It is the most frequent adult 
onset MD, with a worldwide prevalence of 14 per 100,000 population 
and more than 10 times higher in the Saguenay-Lac-Saint-Jean region 
of Quebec (1). It is an autosomal dominant disorder resulting from an 
unstable myotonin kinase gene at 19q13.3.
Hypoventilation in DM may be related to respiratory muscle weak-
ness, upper-airway obstruction, reduced chest wall compliance or be 
related, in some patients, to a reduced CO2 responsiveness (2). 
Hypercapnia in DM may be present even with relative preservation of 
VC and maximal breathing capacity. Other features of DM include myo-
tonia, cardiac conduction defects (3), variable cognitive impairment and 
personality disorders (4,5) that create challenges in establishing relation-
ships in social life and in providing respiratory care. Respiratory failure is 
a major cause of death among DM patients. Aspiration pneumonia and 
perioperative pulmonary complications are common (1).
Key evidence
Very few articles address long-term ventilatory support for patients with 
chronic respiratory failure related to DM. Only a few studies investigat-
ing nonspecific NMDs included some DM patients. Only one relevant 
case series dedicated to long-term ventilation for DM patients was found 
(6). This study was a descriptive analysis of 16 DM patients referred 
for assisted ventilation. The authors describe a good physiological 
response to assisted ventilation but a lower compliance with therapy 
than patients with other NMDs. There are insufficient data to com-
ment about the impact of long-term ventilatory support on HRQoL for 
patients with DM. Other recommendations must be extrapolated from 
key evidence for HMV in other groups of NMDs (Section X). 
Conclusion
Recommendations are based on one specific study of home ventilated 
DM patients (6); a few studies about respiratory pathophysiology (2,7,8); 
other features (1,3,4,5,9,10) of DM; recommendations made for HMV 
in other groups of NMDs (11-15); and the consensus of the HMV 
committee.
Long-term ventilatory support for patients with myotonic dys-
trophy must be considered when there is daytime hypercapnia or 
symptoms and signs of nocturnal hypoventilation. Because of some 
biopsychosocial issues, adherence to long-term ventilatory support 
may be lower in DM patients, and they may require extra support from 
caregivers and health care professionals. Selection of an appropriate 
ventilator and interface for each patient is an important aspect of 
management in this group of patients. Because of facial muscle weak-
ness, a considerable number of patients may have oral air leak when 
using nasal masks so they often require a full oronasal mask.
Beyond the scope of these HMV recommendations, caregivers 
must consider other important issues of DM patient management: 
the need for periodic assessment of cardiac conduction, indications 
for cardiac pacemaker implantation (16), occasional usefulness of 
psychostimulant drugs such as modafinil for idiopathic daytime 
sleepiness (17), and awareness of increased risk of anesthetic and 
surgical complications (18).
SECTION XI. RECOMMENDATIONS
1. Obtain six to 12 monthly clinical assessment of symptoms of 
daytime or nocturnal hypoventilation. (Grade of 
recommendation 1C)
2. Obtain yearly VC and consider daytime PaCO2 measurement, 
even with mild reductions of VC when patients exhibit 
symptoms of hypoventilation. (Grade of recommendation 1C)
3. Consider overnight oximetry or polysomnography when there 
are symptoms of nocturnal hypoventilation. (Grade of 
recommendation 1C)
4. Long-term NIV should be offered to patients with daytime 
hypercapnia or symptomatic nocturnal hypoventilation as for 
other NMDs. (Grade of recommendation 1C)
5. Carefully assess motivation and ability to adhere to treatment 
with patients and their caregivers before initiating long-term 
ventilatory support. (Consensus)
6. Reassess every six months to verify treatment adherence and 
provide extra help and motivation as needed. (Consensus)
7. Assess airway clearance ability with PCFs and implement 
cough-assistance strategies (Section I. Airway Clearance). 
(Grade of recommendation 1C)
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SECTION XII. HMV FOR PATIENTS WITH  
POST-POLIO SYNDROME
Introduction
Late-onset of respiratory problems in post-polio syndrome (PPS) often 
occurs in individuals who initially exhibit respiratory muscle involve-
ment (1,2). Several series have shown an increased risk of respiratory 
failure with VCs <50% predicted (2-4). Scoliosis, respiratory infec-
tion, obesity and concurrent lung disease may play a role in the respira-
tory deterioration; however, the onset of nocturnal hypoventilation is 
often insidious (1,3,5,6).
Key evidence
There are no RCTs on the initiation of HMV in PPS. Recommendations 
informing this section are based on descriptive retrospective and pro-
spective series of mixed populations of patients including those with 
PPS and consensus of the expert HMV committee.
Conclusion
There is little evidence to suggest that patients with PPS who develop 
respiratory insufficiency should be treated differently from other 
patients with slowly progressive NMD. When VC falls below 50%, 
evaluation for possible hypoventilation should be considered (or 
sooner if symptoms are present); however, this is based on low-quality 
evidence. A Cochrane Systematic Review of nocturnal mechanical 
ventilation for chronic hypoventilation secondary to NMDs and chest 
wall disorders only included a few PPS patients in the mixed popula-
tion of patients (7). Although the evidence of therapeutic benefit was 
weak, it supported the suggestion that the symptoms of chronic hypo-
ventilation were alleviated. Prospective and retrospective series report 
reversal of symptoms and signs of hypoventilation, and fairly good 
five-year survival data after institution of noninvasive HMV (8-14).
SECTION XII. RECOMMENDATIONS
1. Yearly assessment of VC is recommended from the time of 
presentation of PPS. (Grade of recommendation 1C)
2. If VC >50% with symptoms of hypoventilation, perform 
measurements of daytime ABGs, overnight oximetry and 
consider polysomnography. (Grade of recommendation 1C)
3. When VC <50%, perform ABG analysis and/or nocturnal 
oximetry yearly. (Grade of recommendation 2C)
4. With confirmation of the presence of chronic 
hypoventilation, offer NIV. (Grade of recommendation 1C)
5. Assess airway clearance ability with PCFs and implement 
cough assistance strategies (Section I. Airway Clearance). 
(Grade of recommendation 1C)
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SECTION XIII. ETHICAL ISSUES IN THE CARE OF 
HOME-VENTILATED PATIENTS
Introduction
HMV is accompanied by several complex and unique ethical issues 
and perspectives. It challenges the traditional framework of care 
provided in a hospital setting, introducing a wide array of new chal-
lenges and experiences. Home ventilation necessarily promotes 
certain fundamental ethical principles, such as respect for autonomy 
and independence of patients, while raising new concerns such as 
isolation, vulnerability and safety. In a home setting, there exist many 
variables within each environment that need to be addressed on an 
individual and personal level (1). Furthermore, HMV may also play 
a key role in issues surrounding the allocation of scarce resources 
because it not only fosters greater independence for patients requiring 
this assistance, but also increases availability in the number of limited 
beds in intensive care units (2-5).
Key evidence
A survey of the current literature on the ethics of HMV revealed that 
there is little written in this field regarding specific ethical concerns 
raised in the home environment for these patients. Evidence surround-
ing the present trend to promote home health care and transitioning 
patients back to their home environments is explored and examined to 
demonstrate the importance and extraordinary benefit of a community-
based health care. Furthermore, there is much evidence to reveal that 
HMV is also a more cost-effective method to alleviate strains on scarce 
health care resources, along with providing enormous mental and 
emotional benefits for patients and family members (6-8). A variety of 
studies reveal a generally positive impression of HMV among patients 
due to the increased independence experienced by these individuals 
(3,7). Another area that needs much more research and investigation 
is that of relative safety of patients receiving HMV due to the number 
of unknown factors associated with care in the community (9,10).
Conclusion
In the context of HMV, patients, their families and clinicians face a 
wide variety of pressing ethical issues and dilemmas. It is important for 
health care professionals to assist stakeholders involved in the decision-
making process using a respectful and sensitive approach to both 
identify and address these issues in a timely, effective and reflective 
manner. Ethical considerations and concerns reviewed in this chapter 
aim to promote professional attributes that compliment moral princi-
ples, professional standards and legal maxims in this unique thera-
peutic alliance. This section illustrates the multidimensional processes 
necessary to assist patients who require HMV. Some of these dimen-
sions include QoL concerns for the patient and family members, 
advance care planning and caregivers’ burden (11-15). There are 
many factors and considerations that must be examined and addressed 
to provide patients with the best possible care based on the patients’ 
values and desires, while respecting the needs and health of 
caregivers.
SECTION XIII. RECOMMENDATIONS
1. Physicians must actively work collaboratively with the 
patient, family members and other health professionals 
involved in the health care decision-making process while at 
all times maintaining respect for patient autonomy, dignity 
and confidentiality. (Consensus)
2. It is important to proactively counsel capable patients and 
establish clear advanced directives (regarding issues such as 
crisis management and end-of-life care) in a timely manner, 
ensuring that patients fully understand and appreciate the 
reasonably foreseeable outcomes of their decisions. Physicians 
must work with patients to help prioritize their values, 
interests and preferences.(Consensus)
3. When considering the most appropriate location for ongoing 
ventilation issues relating to safety and the patient’s values, 
beliefs and preferences must be the primary considerations for 
making such decisions providing optimal independence, 
respect for patient autonomy and increased quality of life. 
(Consensus)
4. In the event that the patient lacks decisional capacity 
regarding specific treatments, substitute decision-makers and 
clinicians must incorporate the patient’s advance care 
directives in the decision-making process or, where there are 
no known advance care directives, to act in the patient’s ‘best 
interests’. (Consensus)
5. One must recognize one’s own biases and endeavor to 
participate in a collaborative and fair decision-making process 
that primarily addresses, reflects and respects the values and 
wishes of the patient. (Consensus)
6. A plan of care should involve full-disclosure of pertinent 
information and a clear and coherent strategy, which would 
enable the patient to make fully informed decisions. This will 
allow any members participating in the patient’s care to be 
held accountable for their duties and obligations. (Consensus)
7. Given the reality of scarce resources, any process of allocating 
limited care resources must be in accordance with distributive 
justice and due process. (Consensus)
8. The well-being of caregivers and the exhausting 
responsibilities of care must be considered. Caregivers should 
be supported, educated with regard to healthy coping 
strategies, and provided with some form of respite care 
whenever possible and desirable. (Consensus)
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